Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered free to relatives of people with T1D to evaluate their personal risk of developing the disease. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.
- Relatives of people with T1D are 15 times more likely to develop the disease than the general population.
- Increased risk of developing T1D is linked to the presence of five diabetes-related autoantibodies.
- The JDRF, ADA and Endocrine Society now classify having two or more of these autoantibodies as early stage T1D.
You qualify for free risk screening if you:
- Are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D (ages 3-45 in the United Kingdom)
- Are between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D (ages 3-20 in the United Kingdom)
- Have not been diagnosed with diabetes
TrialNet currently does not offer re-screening.
Do not register if previously screened as negative in TrialNet.
Your sample cannot be used and will be destroyed.
T1D risk screening will detect if you are in the early stages of T1D. Nearly all people that test positive for two or more diabetes-related autoantibodies will develop the disease.
Please note that due to COVID-19, there may be a delay in receiving your TrialNet Pathway to Prevention Screening results after participating. For up to date information on TrialNet’s response to COVID19 click here: